Stockscreener 앱 받기
15.02
0.47%
0.07
시간 외 거래:
15.02
전일 마감가:
$14.95
열려 있는:
$14.885
하루 거래량:
50,567
Relative Volume:
0.60
시가총액:
$199.85M
수익:
$116.26M
순이익/손실:
$-11.08M
주가수익비율:
-18.97
EPS:
-0.7917
순현금흐름:
$1.04M
1주 성능:
-0.27%
1개월 성능:
-0.53%
6개월 성능:
+64.15%
1년 성능:
+30.61%
1일 변동 폭
$14.88
$15.39
1주일 범위
$14.58
$15.49
52주 변동 폭
$7.8701
$16.49
Anika Therapeutics Inc Stock (ANIK) Company Profile
명칭
Anika Therapeutics Inc
전화
(781) 457-9000
주소
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
15.02 | 198.92M | 116.26M | -11.08M | 1.04M | -0.7917 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | B. Riley Securities | Buy |
| 2024-11-01 | 재확인 | Barrington Research | Outperform |
| 2023-08-14 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 재개 | Stephens | Equal-Weight |
| 2022-03-09 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 개시 | Stephens | Overweight |
| 2021-07-16 | 개시 | UBS | Neutral |
| 2020-12-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | 업그레이드 | Sidoti | Neutral → Buy |
| 2020-01-10 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 개시 | BWS Financial | Sell |
| 2019-09-24 | 재확인 | Barrington Research | Outperform |
| 2019-09-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | 업그레이드 | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2018-07-27 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 재확인 | Barrington Research | Outperform |
| 2016-05-09 | 업그레이드 | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 재확인 | Barrington Research | Outperform |
모두보기
Anika Therapeutics Inc 주식(ANIK)의 최신 뉴스
Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anika Therapeutics Inc (ANIK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Anika Therapeutics Inc (ANIK) Cash Flow - TradingKey
Anika Therapeutics, Inc. Revenue Breakdown – BX:AKP - TradingView
Anika Therapeutics Inc (ANIK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Anika Therapeutics (ANIK) 2026 CG Musculoskeletal Conference Summary - Quartr
Anika Therapeutics (ANIK) Proxy filing Summary - Quartr
Anika Therapeutics (ANIK) Q4 2025 earnings summary - Quartr
Anika Therapeutics (ANIK) AGM 2026 Summary - Quartr
BlackRock Portfolio Management (NASDAQ: ANIK) discloses 4.1% Anika Therapeutics ownership - Stock Titan
Discipline and Rules-Based Execution in ANIK Response - Stock Traders Daily
Anika Therapeutics Expands Revolving Credit Facility Agreement - The Globe and Mail
Anika Therapeutics to issue Q2FY26 results on July 29 - scanx.trade
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026 - GlobeNewswire
Anika Therapeutics Enters Fifth Amendment To Credit AgreementSEC Filing - TradingView
Anika Therapeutics Extends $50M Revolver to 2031 With Bank of America; Upsize Option to $100M - TradingView
Anika Therapeutics (NASDAQ: ANIK) updates $50M revolving credit line terms - Stock Titan
Anika Therapeutics, Inc. Amends and Extends $50 Million Senior Revolving Credit Facility with Bank Of America, N.A - marketscreener.com
Price to book forward of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView
Price to earnings forward of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView
Anika Therapeutics Edges Higher Amid Consolidation: ANIK Stock Tests Key ResistanceALMA Signal - dars.gov.et
Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine - Traders Union
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell 2000 Defensive Index - marketscreener.com
Early MRI scans uncover hidden risks in rotator cuff repair, Integrity Implant System data show - Traders Union
Anika Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANIK) - TradingView
ANIK Forecast — Price Target — Prediction for 2027 - TradingView
Anika Therapeutics unveils Hyalofast cartilage repair scaffold using Hyaff hyaluronic acid technology - Traders Union
Behavioral Patterns of ANIK and Institutional Flows - Stock Traders Daily
Anika Shareholders Approve Directors and Expanded Incentive Plans - TipRanks
Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant - Stock Titan
Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares - Stock Titan
Anika Therapeutics (ANIK) director awarded 10,402 RSUs in stock grant - Stock Titan
[Form 4] Anika Therapeutics, Inc. Insider Trading Activity - Stock Titan
Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant - Stock Titan
Anika Therapeutics increases equity plan shares under amended omnibus and ESPP - TradingView
Anika Therapeutics (NASDAQ: ANIK) shareholders back equity plans and director slate - Stock Titan
Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Anika Therapeutics (ANIK) Q1 2026 Earnings: Massive EPS Surprise Driven by Operational EfficiencyGuidance vs Actual - dars.gov.et
Biologics may shift outcomes in tendon injuries, Anika Therapeutics explores - Traders Union
Anika Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Anika Therapeutics Inc (ANIK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Anika Therapeutics Inc (ANIK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Anika Therapeutics Inc (ANIK) Institutional Confidence - TradingKey
Anika Therapeutics introduces Cingal as only approved HA and corticosteroid combination for OA pain - Traders Union
(ANIK) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Anika Therapeutics (ANIK) Holds Steady Near Support Amid Low VolumeMonthly Profile - newsline.com
Anika Therapeutics Q1 2026 Earnings: Massive EPS Beat Fuels OptimismConsensus Forecast Report - newsline.com
Anika Therapeutics (ANIK) Edges Higher as Shares Test Key Resistance LevelsInside Day Breakout - newsline.com
Anika Therapeutics Inc (ANIK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anika Therapeutics Inc 주식 (ANIK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Griffin Stephen D. | President and CEO |
Apr 30 '26 |
Buy |
12.29 |
12,200 |
149,881 |
36,163 |
0.30%
2.01%
자본화:
|
볼륨(24시간):